Open AccessOverexpression of KDM5B/JARID1B is associated with poor prognosis in hepatocellular carcinoma
Author(s) -
Yoshinobu Shigekawa,
Shinya Hayami,
Masaki Ueno,
Atsushi Miyamoto,
Norihiko Suzaki,
Manabu Kawai,
Seiko Hirono,
Ken-ichi Okada,
Ryuji Hamamoto,
Hiroki Yamaue
Publication year - 2018
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.26144
Subject(s) - demethylase , hepatocellular carcinoma , epigenetics , medicine , cancer research , cancer , oncology , liver cancer , overall survival , biology , genetics , gene
Hepatocellular carcinoma (HCC) has high potential for recurrence, even in curative operative cases. Although several molecular-targeting drugs have been applied to recurrent HCC, their effectiveness has been limited. This study therefore aims to develop novel cancer drugs through protein methylation.